ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,487.03
0.25%
Dow Jones
38,834.86
0.15%
US Dollar vs MXN
18.44185
0.04%
Brent Oil
84.525
-0.20%
Bitcoin
65,153.61
0.29%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. GeoVax Labs Inc (GOVXW)

  7. GeoVax Labs Inc (GOVXW) Noticias

GOVXW GeoVax Labs Inc

0.067
0.0402 (150.00%)
18 Jun 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
GeoVax Labs Inc GOVXW NASDAQ Warrant Capital Accionario
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.0402 150.00% 0.067 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
0.0302 0.0302 0.056449 0.0532 0.0268
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
18/6/202412:13EDGAR2Form 8-K - Current report
07/6/202415:01EDGAR2Form S-1 - General form for registration of securities under..
24/5/202415:04EDGAR2Form 8-K - Current report
23/5/202415:07EDGAR2Form 8-K - Current report
21/5/202416:23EDGAR2Form 8-K - Current report
21/5/202411:32EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
15/5/202415:03EDGAR2Form 8-K - Current report
14/5/202416:09EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
14/5/202416:09EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
14/5/202416:08EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
14/5/202416:07EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
14/5/202415:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
04/4/202411:30GLOBEGeoVax Presents Data on GEO-CM04S1, a Next Generation..
28/3/202408:00GLOBEGeoVax to Present Data on GEO-CM04S1, a Next Generation..
12/3/202408:00GLOBEGeoVax to Present at the 36th Annual Roth Conference
06/3/202408:00GLOBEGeoVax Achieves Milestone in Transition to Commercially..
29/2/202415:00GLOBEGeoVax Reports 2023 Year-End Financial Results and Provides..
22/2/202408:00GLOBEGeoVax to Report 2023 Financial Results and Provide..
19/2/202408:00GLOBEGeoVax to Present at the 2024 BIO CEO & Investor Conference
13/2/202408:00GLOBEGeoVax Announces Multiple Patent Issuances and Allowances
06/2/202408:00GLOBEGeoVax Reports Positive Interim Data From Phase 2 Clinical..
29/1/202408:00GLOBEGeoVax Announces 1-for-15 Reverse Stock Split to Regain..
08/1/202408:00GLOBEGeoVax Appoints Dr. Marc Pipas as Executive Medical..
04/1/202408:00GLOBEGeoVax Announces Gedeptin® Patient Enrollment Closure for..
03/1/202408:00GLOBEGeoVax Announces Issuance of Malaria Vaccine Patent
27/12/202308:00GLOBEGeoVax to Present at Biotech Showcase During J.P. Morgan..
19/12/202308:00GLOBEGeoVax Expands Rights Under NIH COVID-19 License to Include..
30/11/202315:30GLOBEGeoVax Hemorrhagic Fever Vaccine Data Presented at World..
29/11/202308:00GLOBEGeoVax to Participate in Upcoming December Investor Events
28/11/202308:00GLOBEGeoVax COVID-19 Vaccine Clinical Data Presented at World..
14/11/202308:00GLOBEProgress on GeoVax’s Universal Coronavirus Vaccine..
08/11/202315:00GLOBEGeoVax Reports Third Quarter 2023 Financial Results and..
31/10/202308:00GLOBEGeoVax to Report Third Quarter 2023 Financial Results and..
30/10/202308:00GLOBEGeoVax Commences Site Expansion for Phase 2 Trial of..
25/10/202308:00GLOBEGeoVax to Participate in Upcoming November Investor and..
24/10/202308:00GLOBEGeoVax Update: Clinical and Operational Progress Toward..
09/10/202308:00GLOBEGeoVax Receives Notice of Allowance for Marburg Vaccine..
05/10/202308:00GLOBEGeoVax Receives Notice of Allowance for HIV Vaccine Patent
27/9/202308:00GLOBEGeoVax to Participate in Upcoming October Investor and..
26/9/202308:00GLOBEGeoVax Secures Multi-Product License for ProBioGen's..
20/9/202308:00GLOBEGeoVax Next-Generation COVID-19 Vaccine Data Presented at..
19/9/202308:00GLOBEGeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent..
12/9/202308:00GLOBEGeoVax Presents Corporate Update at the H.C. Wainwright 25th..
11/9/202308:00GLOBEGeoVax Completes Enrollment of Phase 2 Trial for..
31/8/202308:00GLOBEGeoVax to Present at the H.C. Wainwright 25th Annual Global..
28/8/202308:00GLOBEGeoVax Receives Notice of Allowance for Malaria Vaccine..
10/8/202308:00GLOBEGeoVax Announces First Patients Vaccinated in Phase 2..
09/8/202315:00GLOBEGeoVax Reports 2023 Second Quarter Financial Results and..
26/7/202308:00GLOBEGeoVax to Report Second Quarter 2023 Financial Results and..
24/7/202308:00GLOBEGeoVax Announces Issuance of Ebola Vaccine Patent

Su Consulta Reciente

NASDAQ
GOVXW
GeoVax Labs
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados